Edap TMSFOCL +1.91%53 3-Year RORE % is 13.86 as of Mar. 2026. GuruFocus rates FOCL with a GF Score™ of 53/100 and a GF Value™ of $4.52 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 111 Medical Distribution companies, Edap TMS ranks worse than 51.35% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Edap TMS's 3-Year RORE % for the quarter that ended in Mar. 2026 was 13.86%.
The industry rank for Edap TMS's 3-Year RORE % or its related term are showing as below:
FOCL's 3-Year RORE % is ranked worse than 51.35% of 111
companies
in the Medical Distribution industry
Industry Median: 14.45
vs FOCL: 13.86
Edap TMS (NAS:FOCL) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Edap TMS 3-Year RORE % Related Terms
Edap TMS 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Edap TMS's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Edap TMS's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS 3-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Edap TMS's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Edap TMS (FOCL) has a 3-Year RORE % of 13.86 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Edap TMS and its competitors. According to the industry distribution chart, Edap TMS ranks #57 out of 111 companies in the Medical Distribution industry, placing it in the top 51.4%.
Is Edap TMS's 3-Year RORE % too high?
Edap TMS's current 3-Year RORE % is 13.86. The Medical Distribution industry median 3-Year RORE % is 14.45. Edap TMS's value of 13.86 is 4.1% below this industry median. Based on the distribution chart, Edap TMS ranks #57 out of 111 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Edap TMS has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's 3-Year RORE % compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #57 out of 111 companies for 3-Year RORE %. This places Edap TMS in the lower half of its industry. The industry median 3-Year RORE % is 14.45. Edap TMS's value of 13.86 is 4.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Distribution company?
The median 3-Year RORE % among Medical Distribution companies is 14.45, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edap TMS's current 3-Year RORE % of 13.86 is 4.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Edap TMS and its competitors. For the Medical Distribution industry, the median 3-Year RORE % is 14.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current 3-Year RORE % is 13.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.52, compared to a current price of $5.08 — trading 12.3% above its estimated fair value. The current 3-Year RORE % is 13.86 and 4.1% below the Medical Distribution industry median of 14.45. Edap TMS's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Edap TMS (FOCL), the current 3-Year RORE % is 13.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FOCL) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of $5.08 is trading 12.3% above its estimated GF Value™ of $4.52.
GuruFocus considers Edap TMS to be Modestly Overvalued.
Key valuation signals for FOCL:
3-Year RORE %: 13.86
GF Value™: $4.52 vs. price of $5.08 (12.3% above fair value)
Industry Position: 4.1% below the Medical Distribution median (#57 of 111)
No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
53GF Score
Get the complete analysis for FOCL
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOCL has been successfully added to your 
